Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

Met primary study endpoints: good safety profile and reduction in central subfield thickness First oral therapy to demonstrate reduction in macular edema; supports potential for early disease...

Related Keywords

,Christen Baglaneas ,Quan Dong Nguyen ,Araj Agrawal ,Arshad Khanani ,Tirtht Patel ,Nasdaq ,Reno School Of Medicine ,Securities Exchange ,University Of Nevada ,Rezolute Inc ,Stanford University School Of Medicine ,Head Of Ophthalmological Clinical Development At Rezolute ,Byers Eye Institute ,Stanford University School ,Scientific Advisory ,Clinical Professor ,Reno School ,Primary Investigator ,Vice President ,Ophthalmological Clinical Development ,Corrected Visual Acuity ,Early Treatment Diabetic Retinopathy Study ,Diabetic Retinopathy Severity Score ,Study Eye ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Risk Factors ,Annual Report ,Quarterly Reports ,